Comments
Glenmark Pharmaceuticals , a research led, integrated global pharmaceutical company, today announced that it has received approval from the Ministry of Healthcare, Russia, to market Montlezir (Levocetirizine Dihydrochloride 5mg + Montelukast Sodium 10mg) film coated tablets as a prescription product for the treatment of seasonal and perennial allergic rhinitis in patients above 15 years of age. Montlezir is expected to be available in the Russian market in Q3 FY2019-20. Shares of Glenmark closed 2.55 per cent lower at ₹324.80 on the BSE.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.